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Abstract: Dynamic regulation of specific molecular processes and cellular phenotypes in 
live cell systems reveal unique insights into cell fate and drug pharmacology that are not 
gained from traditional fixed endpoint assays. Recent advances in microscopic imaging 
platform technology combined with the development of novel optical biosensors and 
sophisticated image analysis solutions have increased the scope of live cell imaging 
applications in drug discovery. We highlight recent literature examples where live cell 
imaging has uncovered novel insight into biological mechanism or drug mode-of-action. 
We survey distinct types of optical biosensors and associated analytical methods for 
monitoring molecular dynamics, in vitro and in vivo. We describe the recent expansion of 
live cell imaging into automated target validation and drug screening activities through the 
development of dedicated brightfield and fluorescence kinetic imaging platforms. We 
provide specific examples of how temporal profiling of phenotypic response signatures 
using such kinetic imaging platforms can increase the value of in vitro high-content 
screening. Finally, we offer a prospective view of how further application and development 
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of live cell imaging technology and reagents can accelerate preclinical lead optimization 
cycles and enhance the in vitro to in vivo translation of drug candidates. 
Keywords: imaging; intravital; high-content; temporal; fluorescence; drug discovery; 
biomarkers; translation; efficacy 
 
1. Introduction: Challenges in Preclinical Drug Discovery 
The past two decades have witnessed significant scientific and technical advances in the fields of 
drug discovery and translational medicine. Despite increased knowledge of disease mechanism and 
higher levels of financial investments in drug discovery research and development (R&D) the number 
of novel medicines approved by regulatory agencies such as the US Food and Drug Administration 
(FDA) has been in steady decline, with 50% fewer new molecular entities (NME) approved in the past 
five years compared with the previous five year period [1]. The development of truly innovative 
medicines that provide superior efficacy and safety in clinical settings over existing standards of care 
represents a formidable challenge. High attrition rates of candidate drugs in late stage preclinical 
development or clinical trials due to toxicity and limited efficacy suggests current pre-clinical drug 
discovery strategies are sub-optimal and poorly predict clinical outcome. The conventional target-
directed drug discovery approach, where candidate drugs are developed on the basis of potency and 
selectivity against a single nominated target complements high-throughput serendipitous screening 
strategies of large chemical libraries. However, high costs, protracted timelines, low success rates and 
impending patent expirations suggest that the target directed drug discovery approach, on its own, no 
longer represents an effective R&D strategy.  
Alternative drug discovery strategies that offer faster, more cost-effective and more opportunistic 
drug development approaches for new chemical entities, existing drug portfolios, multi-targeted agents 
and drug combinations are urgently required. A critical requirement of any new drug discovery 
approach is to provide greater predictivity of clinical response over existing methods and thus more 
productive translation of preclinical findings to clinically effective therapy. Recent advances in next 
generation sequencing, quantitative proteomics, RNAi technology, systems biology approaches and 
quantitative in vitro and in vivo imaging all embrace the biological complexity of disease and offer 
alternative strategies for target selection, target validation, candidate drug profiling and patient 
stratification [2,3]. Quantitative in vitro and in vivo imaging represents a more holistic approach to 
evaluation of drug efficacy, providing an unbiased and thus more opportunistic assessment of drug 
response in complex biological systems. Real-time image based analysis of drug response upon target 
activity and pathophysiology in vitro and in vivo may accelerate drug development timelines, reduce 
costs, provide novel mechanistic insight into adaptive response and increased clinical predictivity 
when applied appropriately to relevant model systems. In this review article we describe the latest 
research tools and approaches that facilitate live cell imaging and which are advancing the field of 
dynamic in vitro and in vivo imaging applications in drug discovery. 
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2. Live Cell Imaging In Vitro 
Optical microscopes developed in the early 17th century represent the original transformative 
scientific technology for detailed physiological analysis of tissue and cell biology. Traditionally, 
microscopic imaging in research has been applied subjectively through manual application to small 
numbers of experimental or clinical specimens. However, recent developments of fully automated 
fluorescent microscopic acquisition platforms and associated image analysis algorithms have enhanced 
the throughput and statistical robustness of quantitative imaging. These advances have facilitated the 
integration of quantitative microscopic imaging into the drug development process and created the new 
discipline of high content screening. High content microscopic platforms and image analysis tools 
have evolved rapidly over the last 5 years and become established to different levels of sophistication 
and application within the pharmaceutical and biotechnology industry [4,5]. 
The widespread adoption of high content screening platforms by the pharmaceutical and 
biotechnology industry indicates a new trend in incorporating complex biological endpoints into drug 
discovery. High content screening is typically placed as a secondary screening strategy to confirm the 
quality of hits, identified through high throughput biochemical screening. However, high content 
assays are increasingly being applied to primary screening approaches, and have been proposed as a 
strategy to reduce attrition at later stages in drug development by frontloading the evaluation of novel 
target classes, chemical libraries and biologic therapeutics in more physiological cell systems [6]. 
Several publications describe the utility of high content imaging and analysis for profiling drug 
mechanism and defining structure activity relationship based upon phenotypic endpoints suggesting 
that quantitative imaging may offer an alternative approach to target-directed drug discovery [7-10]. 
The impact of high content biology on increasing the predictivity of the drug discovery process and 
transforming R&D productivity, in terms of delivering more successful therapies into the clinic, 
remains to be determined and will largely be dictated by the quality of the underlying biological 
models being subjected to investigation. 
Typical high content cell-based screens employ fixed endpoint assays that provide a snapshot in 
time of a cellular response to pharmacological or molecular perturbation. In a similar manner to image-
based immunohistochemical assessment of preclinical drug studies, such image based snapshots 
provide a reflection of pharmacological response at the time of sampling. Extension of image-based 
analysis to live cells, fresh tissue or live in vivo models in a time-resolved manner provides a more 
complete picture of dynamic biological processes through greater spatial and temporal understanding. 
Temporal analysis of drug response provides a number of unique advantages that enhance and 
complement fixed endpoint studies including: Quantification of transient phenotypic responses; 
Optimization of appropriate timepoints for endpoint studies; Interpretation of conflicting findings from 
endpoint studies that often arise from dynamic reversible processes that operate under precise temporal 
and spatial control; Characterization of adaptive responses; Determination of accurate scheduling and 
dosing regimes; Provision of additional data points of biological events collected over a time series, 
facilitating more robust quantitative analysis from less specimens. In the following sections of this 
article we shall review the development of the latest optical tools and enabling technology platforms, 
specifically optimized for live cell imaging applications in vitro and in vivo. We cite literature 
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examples where live cell imaging has provided novel insight of pathophysiogical mechanism and drug 
response that cannot be extracted from fixed endpoint studies. 
3. Live-cell Imaging in Vitro: Technical Advances and Novel Applications 
3.1. Automated imaging platforms 
Traditional time-lapse epifluorescent and confocal image acquisition microscopes provide detailed 
temporal and spatial analysis of cellular function. Throughput of such instruments is, however, 
restricted to one or a few samples per experiment, limiting their application within drug discovery. 
Most automated high content imaging microscopes can also be applied to live-cell kinetic studies 
where an environmental chamber is integrated onto the platform, however, throughput and analysis are 
once again rate-limited and environmental conditions are not optimal for long-term studies. Recent 
developments of more innovative microscopic configurations where the microscopic optical 
instrumentation is placed within a robust environmental chamber represent a significant technological 
advance in dynamic cell imaging. Such systems exemplified by IncuCyteTM; Cell-IQTM and Biostation 
CTTM incorporating software enabling remote control of, image acquisition, filter optic configurations 
and image analysis are optimized for long term kinetic studies across multiwell plates. This new 
generation of live-cell imaging microscopes increases the throughput and flexibility of examining 
dynamic cellular processes in response to multiple molecular or pharmacological intervention studies.  
The IncuCyte-FLRTM is a compact, automated fluorescent and brightfield kinetic imaging platform 
that can be accommodated within a standard tissue culture incubator. The standard IncuCyte-FLRTM 
system can accommodate up to six 384-well plates to enable sequential monitoring of molecular and 
cell dynamics across multiple samples or drug treatment regimes in a single study. The IncuCyteTM 
platform also incorporates a suite of specific application modules comprising of image analysis 
algorithms and custom-designed consumables to facilitate automated monitoring of specific cellular 
processes such as cell growth, cell migration into a wounded monolayer, angiogenesis and apoptosis 
(Figure 1).  
Further visual inspection and detailed analysis of kinetic responses reveal additional information 
upon cellular physiology. For example, long-term monitoring of cell migration with the IncuCyteTM, 
clearly distinguishes protrusion of the leading edge, lamellipodia dynamics and uropod (rear) 
retraction (Figure 2). Such analysis of dynamic cellular events provides insightful mechanistic 
information that can assist with defining drug or target mechanism-of-action studies. 
The Cell-IQTM represents a fully integrated incubator, phase contrast and fluorescent image 
acquisition system linked to image analysis software based upon “machine vision” artificial 
intelligence approaches. The Cell-IQTM acquisition software provides a flexible interface enabling 
fully automated or user defined image acquisition across 2D and 3D cell culture systems. The use of 
machine vision based training provides a flexible approach to monitoring proportions of distinct 
cellular phenotypes within complex samples such as co-culture models. In addition to classifying 
phenotypes other processes such as cell attachment, migration velocity, migration direction, neurite 
outgrowth, vesicle formation, angiogenesis and stem cell differentiation have all been recorded on the 
Cell-IQTM platform. The Cell-IQTM system enables robust kinetic profiling of phenotypic response 
following drug treatment including transient and long-term events (Figure 3). The temporal profile of 
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phenotypic response and transient events often vary between cell type, drugs and drug doses (Figure 3). 
Thus, kinetic profiling provides robust phenotypic analysis of drug response and facilitates the 
selection of the most appropriate timepoints for standard high-content endpoint screens. 
Figure 1. IncuCyteTM kinetic imaging platform and applications. Kinetic monitoring and 
quantification of (A) cell confluence, (B) cell migration following wounding of a 
monolayer of HT1080 fibrosarcoma cells. Data represents wound width (m) at sequential 
time points quantified using the IncuCyte migration application module. (C) Angiogenesis 
in a human primary co-culture model of endothelial (HUVEC) and fibroblast cells where 
HUVECs have been labeled with GFP. Data represents cells treated in co-culture with 
VEGFR2 inhibitor (0.1 M) or vehicle control for 10 days. Tubule area quantified using 
the IncuCyte angiogenesis algorithm. (D) Caspase-mediated apoptosis in a human 
micovascular endothelial cell line (HMEC-1) treated with Staurosporine (0.3 µM) and 
cultured in the presence of NucViewTM caspase substrate. Caspase positive cells quantified 
using the IncuCyte object counting algorithm. n = 3 (error bars are standard deviation). 
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Figure 1. Cont. 
 
 
The Nikon Biostation CTTM platform represents the first multi-objective fluorescent and phase 
contrast microscope integrated with automated plate handling robotics all within a cell-culture 
incubator. Such advances in kinetic imaging platforms have the potential to significantly increase the 
throughput and scope of live-cell studies by enabling more extensive and robust target identification, 
validation and secondary screening applications.  
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Figure 2. Kinetic profiling of cell migration response. Time lapse images obtained from 
the IncuCyte platform demonstrating the polarity and morphology of migrating HT1080 
fibrosarcoma cells following compound treatment. White arrow denotes direction of cell 
movement. The time resolved images clearly demonstrate the impact that compound X has 
upon the adhesive mechanisms regulating cell motility with clear defects in lamellipodia 
formation at the leading edge and uropod retraction at the trailing edge (Figure 2). 
 
The examples provided here highlight the capabilities for new kinetic imaging technology to 
accurately record adapting transient responses that may also include dynamic flux through signaling 
pathways or temporal/spatial oscillations that are not readily detected by standard endpoints. The 
additional information provided by such temporal analysis is likely to provide further insight into drug 
or target mode-of-action and cross-talk between distinct pathways and mechanisms. The temporal 
analysis of phenotypic response also provides valuable insight into pharmacodynamic properties of 
candidate drugs. By relating the kinetics of pharmacodynamic phenotypic response to known in vivo 
pharmacokinetic properties of drug candidates shall facilitate more optimal scheduling and dosing 
strategies for in vivo studies. Thus, such technologies may drive the development of a new class of 
kinetic biomarkers that can be placed earlier in the drug discovery process to ensure more successful 
translation towards in vivo efficacy.  
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Figure 3. Cell-IQTM Kinetic phenotypic profiling of drug response. (A) Machine learning 
based training of cellular phenotypes from phase contrast images. (B) Kinetic monitoring 
of the proportion of each phenotypic class and total cell number (within a single field of 
view) following treatment with different concentrations of colchicine. Data presented 
provides quantitative analysis of transient mitotic arrest phenotype.  
 
 
3.2. Multidimensional imaging 
Multiphoton confocal microscopy offers a number of advantages over conventional fluorescent 
microscopy methods for live cell imaging such as greater depth penetration, better Z-resolution 
improving 3D reconstruction, less phototoxicity and photobleaching of samples. These advances 
facilitate the long term analysis of cell behavior in live-cell cultures and provide more sensitive and 
quantitative analysis of fluorescent reporters or labeled cells within more physiological 3D culture 
systems, thick tissue samples or live in vivo models. Cell migration assays traditionally used for 
monitoring the effect of drug treatments upon cell motility include Boyden chamber type 
transmigration or scratch wound endpoint assays [11,12]. While such assays provide a robust 
quantification of the number and relative proportions of migrating cells they provide limited 
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mechanistic information on cell motility or drug response. Live cell imaging studies have provided 
additional mechanistic insight into heterogeneous mechanisms of cell motility and the effect of drug 
response upon such mechanisms in both 2D and 3D culture systems [13,14]. Multiphoton confocal 
analysis has further characterized several distinct modes of tumor invasion that occur in more 
physiological 3D environments and categorized these as, mesenchymal, amoeboid and collective  
[15-17]. Mesenchymal tumor invasion is characterized by single cell locomotion associated with 
integrin mediated adhesion and matrix metalloproteinase (MMP)–mediated remodeling of extracellular 
matrix (ECM) [15]. Amoeboid invasion is characterized by a spherical, single cell, locomotion 
phenotype that is independent of MMP activity [18]. Collective invasion is characterized by tumor cell 
locomotion as a multicellular sheet associated with both integrin mediated adhesion and MMP-
mediated ECM remodeling. These dynamic imaging studies shed new light on the morphological and 
functional characteristics of multiple tumor invasion mechanisms. Plasticity between distinct tumor 
invasion mechanisms enables rapid adaption of tumor invasion in response to environmental factors 
including pharmacological intervention. Such mechanistic adaptation may explain conflicting 
pharmacological responses observed between distinct tumor cell models and recorded clinical 
resistance to potential anti-invasive therapies such as MMP inhibitors [19]. Further studies using live 
cell confocal microscopy uncover the influence that stromal cell types, within the tumor 
microenvironment, have upon tumor invasion [20]. MMP dependent invasion of fibroblasts through 
3D ECM preparations creates tracks in the ECM environment that facilitates the collective invasion of 
squamous cell carcinoma cells through such tracks [20]. These live-cell imaging studies, therefore, 
uncover a pro-tumorigenic role for stromal cell remodeling of ECM topology to create a more 
permissive microenvironment for tumor invasion. Through further discovery, phenotypic 
characterization and quantification of distinct tumor invasion mechanisms by live-cell imaging, drug 
discovery researchers can begin to tailor their experimental models appropriately to specific target 
classes or to recapitulate multiple drug resistance mechanisms to aid the evaluation of new 
pharmacological interventions that counteract such adaptive responses.  
4. Advanced Imaging Technologies 
4.1. Photactivation, photoswitching, photobleaching and photoinactivation 
Serial site-directed amino acid mutation studies have created genetically engineered fluorescent 
proteins that are photoswitchable from dark to bright, or from one color to another following excitation 
at a specific wavelength [21]. Such photoactivatable probes can be used in live cell systems to track 
cell movement, monitor protein diffusion dynamics, protein stability and cell-substructure function 
[22-28]. Fluorescence recovery after photobleaching (FRAP) offers an alternative approach for 
monitoring protein diffusion and dynamic intracellular processes. FRAP analysis of GFP labeled 
integrin subunits at sites of cell-substrate adhesion has been applied as a quantitative measurement of 
the dynamic turnover of integrin associated adhesions, thus providing both spatial and temporal 
analysis of cell adhesion mechanisms not provided by traditional adhesion assays or endpoint 
measurements [29].  
Photo-reactive proteins can also be exploited to positively manipulate protein activity. Recently, the 
photo-reactive domain of phototropin was fused to a constitutively active mutant of Rac1, causing 
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sterical hindrance and impairing its interaction with downstream effectors [30]. Upon light 
illumination, the photo-reactive domain unwinds and allows the un-caging of the fused protein, leading 
to Rac1 activation. Using this approach light-guided timing and location of protein activation can be 
precisely regulated at sub-cellular resolution. This method has recently been used to show light-
mediated guidance and control of cells movement both in vitro and in vivo [30,31]. Similarly, 
adaptations of light-gated proteins to control upstream regulators of the Rho family GTPases have 
recently been documented to control cell protrusion and migration [32]. Chromophore assisted light 
inactivation (CALI) is a specific technique for locally perturbing protein function through the 
generation of reactive oxygen species (ROS) that destroy specific proteins following excitation of an 
attached fluorophore. This approach provides a precise mechanism for inactivating protein targets with 
improved spatial and temporal control than provided by popular methods of genetic knockout or 
siRNA [33]. Using GFP as a CALI sensor, optical irradiation of GFP-α-actinin but not GFP-FAK 
(focal adhesion kinase) resulted in a loss of actin-fiber association with integrins. These are the first 
studies to demonstrate that FAK is not critical for stress fiber attachment to integrin mediated cellular 
adhesions [33]. The application of light-mediated activation/inactivation of other proteins both 
spatially and temporally in complex biological systems will provide a diverse platform in which to 
validate targets and investigate various drug regimes under appropriate biological context. 
4.2. FRET and FLIM 
Forster Resonance Energy Transfer (FRET) is a technique that monitors the transfer of energy from 
a donor to an acceptor fluorophore when donor-acceptor fluorescent pairs come into close proximity. 
FRET is performed following specific excitation of the donor flurorophore, and subsequent analysis of 
the fluorescent emission properties of the acceptor fluorphore. Alternatively, a change in the 
fluorescent decay rate of the donor can be used to measure FRET and changes in the fluorescent 
lifetime of the donor can be recorded by Fluorescent Lifetime Imaging Microscopy (FLIM) methods. 
The exponential decay rate of the fluorophore signal, rather than its intensity, is used to create the 
images in FLIM and can provide a more robust FRET readout due to less scattering of light or other 
artifacts associated with acceptor excitation/emission. Each fluorophore has unique decay rates, thus 
FLIM can also be used to distinguish between fluorophores in a multiplex assay. The exponential 
decay of fluorophores or autofluorescent biological structures can be altered by physiological events 
and thus label or label-free FLIM may provide an indirect readout of physiological modifications. 
Both FRET and FLIM have been applied to monitor, protein-protein interactions, conformational 
changes in tertiary protein structure or proteolytic cleavage events in live cells [34]. Unlike ratiometric 
FRET, FLIM is independent of the donor concentration and therefore insensitive to bleaching. Specific 
FRET biosensors have been designed to monitor, in live cells, the activity of a number of distinct 
kinase (Src, FAK, EGFR), protease targets (calpain) [35-37] and intracellular signaling of calcium 
[38,39] amongst others [40]. The most common method used for quantification of FLIM reporters is 
Time Correlated Single Photon Counting (TCSPC). However, the application of longitudinal TCSPC 
FLIM to live cell applications is limited by long acquisition times particularly across large fields of 
view or multiple Z-planes. Thus, multiple acquisition of TCSPC FLIM in live cell systems is 
associated with a high risk of photobleaching and photodamage. A new innovation in FLIM 
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technology is the development of, wide-field, time-gated, imaging using a gated optical intensifier 
(GOI) combined with a Nipkow disc confocal microscope that significantly reduces the time for FLIM 
data acquisition to 10 frames per second [41]. These advances have led to the development of high-
speed FLIM systems suitable for high-content analysis of FLIM reporters in live cell and 3D model 
systems across multiple samples [42]. High-speed FLIM has been applied to monitor the interaction of 
Ras protein with Raf binding partners, a key event in the RAS-MAPK signaling cascade, in live-cell 
specimens in a format suitable for chemical or molecular screening [42]. Furthermore, such approaches 
have permitted a multiplexed FRET readout of the spatial and temporal resolution of both Ras 
activation and calcium flux in a single live cell assay [43]. Similarly, the simultaneous investigation of 
intensity based FRET probes within the same cells has recently been used to dissect the synchronized 
activity of individual RhoGTPases during coordinated cell migration [44]. Frequency domain based-
FLIM has also been adapted to allow for fast FLIM in a 96-well high-throughput format for the in situ 
identification of tyrosine phosphorylation networks downstream of EGFR signaling [45]. The potential 
adaptation of these techniques for the simultaneous analysis of different probes within the same cell in 
a high throughput setting will enable the precise temporal and spatial monitoring of target activity and 
associated downstream or compensatory signaling pathways in response to a variety of drug screening 
regimes. 
Lifetime imaging has recently been employed to compare the intrinsic lifetime of ECM proteins 
within spatially distinct regions of human tissue, such as the core or the periphery of a tumor [46]. 
Furthermore, this technique has been applied to evaluate invasive and non-invasive stromal tissue in 
fixed or freshly excised human cancer samples [47]. Lifetime imaging in this manner can provide vital 
intrinsic, contextual, and local environmental information on levels of hypoxia, NADH, the 
constitution of ECM components, and the overall metabolic status at specific areas within the tumor, 
such as detecting necrotic region within the tumor. This application of lifetime imaging to provide a 
histological profile which can document changes in the local tissue micro-environment upon 
therapeutic intervention will be of use in the assessment of drug delivery. Recently, lifetime imaging 
has been utilized in human tissue microarray (TMA) studies to understand not only the tumor status 
but the environment in which different tumor types prosper [48]. FLIM has also been used to obtain 
additional contrast from cells labeled with nuclear dyes (Figure 4) and properties of such dyes have 
been used to detect apoptosis [49] and identify changes in DNA/RNA content for the study of cellular 
proliferation, differentiation and cell cycle [50,51]. Lipid-targeting fluorescent probes (e.g. di-4-
ANEPPDHQ) have also been used for FLIM applications in live cells to probe lipid order in the 
cellular membrane [42,52]. 
 
 
 
Figure 4. In vitro Fluorescent Lifetime Imaging Microscopy (FLIM): Discrimination of 
cellular DNA and RNA. Intensity (left panel) and lifetime images (right panel) of MCF-7 
cells stained with a range of green-fluorescent nucleic acid binding dyes. The dyes are 
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commonly used as nuclear or cell counter stains in standard fluorescent microscopy (left 
panel) but are known to differ from each other in one or more characteristics, including 
DNA/RNA binding selectivity. Here, additional contrast provided by FLIM of Syto15 and 
Yoyo-1 distinguished cytoplasm, nucleus and nucleoli. Contrast observed with Yoyo-1 is 
due to longer lifetime of dye bound to RNA and shorter lifetime of dye bound to DNA 
(data not shown). FLIM contrast observed with other dyes was either minimal (Syto23) or 
offered less contrast across cytoplasmic, nuclear and nucleolar compartments (Syto25, 
Syto16, Syto21, Syto22, Syto20). This study identified dyes appropriate for rapid cell 
image segmentation using FLIM rather than requiring dye multiplexing in either live or 
fixed cells and suggests that additional screening to identify FLIM contrast for biological 
event monitoring e.g. apoptosis or cellular differentiation may be worthwhile. Images 
acquired by Clifford Talbot et al. in the Photonics Group at Imperial College London using 
a laser scanning confocal TCSPC microscope.         
 
4.3. Fluorescent protein complementation 
An alternative approach for monitoring protein-protein interactions dynamically in live cells is 
through the application of bimolecular fluorescent complementation (BiFC) assays [53]. BiFC 
monitors protein-protein interactions by expressing a split fragment of a fluorescent reporter protein on 
each individual protein binding partner. When the protein partners interact the split fluorescent 
reporter proteins complement together forming a functional fluorescent molecule that acts as a positive 
reporter for the protein-protein interaction. Engineered panels of cell lines expressing multiple 
fluorescent protein complementation pairs enables the dynamic profiling of multiple pathways in live 
cells [54]. 
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The methods described above exploit the unique spectral properties of fluorescent molecules 
combined with the spatial and temporal resolution provided by microscopic imaging to enable detailed 
kinetic and spatial analysis of pathway events and cell physiology in live cell systems. These 
approaches provide additional insight and quantitative analysis of dynamic transient events that are not 
obtained from fixed endpoint studies. Specific applications of live cell imaging demonstrating added 
value over fixed endpoint studies include, cell migration, cell-cycle progression, endocytosis, 
autophagy, subcellular translocation, cell-cell interactions, intracellular calcium fluxes, oscillations in 
biochemical signaling and turnover rates of cell adhesions [55-58]. Extension of such live-cell analysis 
approaches to in vitro and in vivo preclinical drug discovery shall enable a more comprehensive 
temporal evaluation of drug response in complex biological systems. Integration of fluorescent 
reporter molecules and spectroscopic techniques with dedicated in vitro and in vivo live optical 
imaging systems shall further enhance the application of live-cell imaging into preclinical drug 
discovery. 
5. Live Cell Imaging In Vivo 
Complimentary advances in advanced imaging technologies, near-infrared fluorescent NIRF 
imaging reagents, intravital microscopic methods and dedicated in vivo optical imaging systems have 
driven the application of fluorescent imaging into live animal models and fresh tissue specimens  
[59-61]. The development and commercial availability of a variety of near-infrared fluorophores and 
nanoparticles optimized for in vivo application (included in Table 1) has stimulated the development 
and adoption of optical in vivo imaging for preclinical drug discovery. Longitudinal in vivo imaging 
studies in live animals provide more detailed information from fewer animals at significant cost 
savings compared with traditional preclinical methods thus, representing an attractive approach for 
preclinical drug evaluation studies. 
5.1. Non invasive in vivo imaging 
Recent advances in in vivo fluorescent imaging technologies include; multispectral imaging, 
tomographic reconstruction and high resolution intravital multiphoton confocal microscopy. Specific 
examples of dedicated fluorescent in vivo imaging systems offering non-invasive analysis of 
fluorescent reporters include the MaestroTM system from Cambridge Research & Instrumentation, Inc. 
(CRi). The MaestroTM platform incorporates a liquid crystal tunable filter and multispectral unmixing 
software to facilitate subtraction of background autofluorescence and multiplexing of multiple 
overlapping fluorophores in vivo. The increase in signal to noise associated with spectral unmixing can 
increase the sensitivity of analyzing distinct fluorescent signals in vivo when compared with standard 
monochrome reflectance imaging approaches [62] (Figure 5). The recent development of the Maestro 
dynamicTM system further facilitates the acquisition of temporal multispectral data enabling 
quantitative assessment of the biodistribution and pharmacokinetic properties of multiple probes in a 
sequential manner. Advances in the development of more sensitive charge coupled device (CCD) 
cameras linked to optimized photon amplification and counting technology such as that exemplified by 
the Photon Imager from Biospace Lab offer maximal sensitivity for both bioluminescent and 
fluorescent in vivo imaging. The intensified CCD technology within the Photon Imager amplifies all 
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light emitted from the specimen by a sequential process of converting photons to electrons, electron 
amplification and conversion back to photons by a phosphorescent screen. As a direct result of this 
process the CCD camera in the Photon Imager is able to record and forward the optical signal emitted 
from in vivo samples at a rapid constant frame rate of 43 Hz facilitating real-time analysis of optical 
reporters. A key consideration for the detection and quantification of optical probes in vivo or in thick 
tissue samples is the scattering of light by biological tissue limiting quantitative assessment of signal 
strength, size and depth. Advances in fluorescent molecular tomography systems such as the FMT2500 
LX, commercialized initially by VisEn Medical and subsequently by Perkin Elmer, provides a 
transmitted light excitation and emission configuration and associated software that compensates for 
the scattering of light through tissue. The FMT reconstruction software provides a more accurate 
assessment of the light emitting signal including robust quantification of size and depth of fluorescent 
reporters at any position in a mouse model [63]. The Ivis® spectrum and Ivis® Kinetic instruments 
from Caliper represent fully integrated non-invasive optical devices that facilitate both non invasive 
bioluminescent and fluorescent imaging in small animal models. The Ivis® systems are highly 
versatile platforms offering both spectral unmixing and single view 3D tomographic capabilities. The 
added sensitivity provided by a highly sensitive electron multiplying charge coupled device (EMCCD) 
camera on the Ivis®Kinetic system enables acquisition of bioluminescent or fluorescent reporter 
signals in milliseconds facilitating real-time analysis of biologically relevant events recorded by 
optical biosensors. The development and application of non-invasive in vivo optical imaging systems 
described above facilitate the longitudinal study of physiological responses, pharmacokinetics and 
pharmacodynamics in preclinical models without the need for sacrificing the animal. However, the 
application of non-invasive imaging is limited by the spatial resolution of images obtained and the 
availability of optimized probe sets.  
Figure 5. Multispectral in vivo imaging. Application of the MaestroTM system to detect and 
differentiate RFP labeled MDA-MB231 breast cancer cells in a live mouse following 
orthotopic implantation in the mammary fat pad. 
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5.2. High resolution intravital imaging 
Advances in intravital confocal microscopy that provide cellular and subcellular resolution of 
biological events in vivo, more akin to in vitro high-content studies, provide a more adaptable platform 
for the development of live-cell in vivo imaging applications [61]. A number of recent technical 
developments have facilitated high resolution confocal microscopy in live in vivo models. The design 
of new lens configurations such as the microprobe lenses supplied by Olympus and miniaturized fiber 
optic fluorescent microscopic endoscopic (FME) devices facilitate physical access and functional 
analysis of deep tissue sites [64]. Such technology has been further developed to enable 
multidimensional fluorescent imaging in vivo with the introduction of fluorescent lifetime 
measurement capability on the Cellvizio endomicroscope platform [65].   
Implantation of tissue window devices such as optically clear glass coverslips in the skin enable 
long-term repeated high-resolution in vivo imaging without the elicitation of artifactual inflammatory 
responses associated with surgical trauma at time of image acquisition (Figure 6A). The design and 
application of tissue window devices for live in vivo imaging represents an increasing trend as 
demonstrated by a number of recent publications. Several studies describe the design of tissue window 
devices tailored to specific tissue sites under examination, including cranial windows [66], mammary 
windows [23] and dorsal skinfold windows [26,67]. Tissue window devices offer a number of 
advantages over alternative surgical exposure methods including the so called “skin flap” method 
including, sample stability, maintenance of tumor environment and repeated long term imaging in 
conjunction with recoverable anesthesia. Furthermore, in our experience the mechanical stability 
offered by the use of dorsal skinfold windows is of significant benefit when acquiring 
photobleaching/photoactivation time series. Two important considerations in the application of tissue 
window devices are the surgical methods of implantation to ensure minimal tissue damage and proper 
sterilization prior to use including anti-bacterial and anti-fungal treatment. Further optimization of the 
design and commercial availability of more cost effective and improved tissue window devices in 
association with approved surgical implantation protocols will provide a significant stimulus to the 
field of “live” in vivo imaging. Specific advantages of applying multiphoton confocal approaches 
together with intravital microscopy include, enhanced spatial resolution, and reduced image 
degradation due to light scattering. Greater depth penetration through tissue, improved optical 
efficiency, better z-registration for 3D reconstruction and less photodamage and phototoxicity enabling 
longer acquisition time and repeated imaging in live specimens. Multiphoton imaging can also provide 
additional detail regarding interactions with the surrounding extracellular tissue microenvironment 
provided by second harmonic signal generation which highlights non-centrosymmetric protein 
structures such as collagen and elastin.  
Specialist microscopy systems that are optimized to facilitate the high resolution imaging of live 
animals are now reaching maturity. One example is the multiphoton multi-point scanning TriM-scope 
from LaVision Biotec. The design rational behind the system is to enhance the acquisition of optically 
sectioned imaging of thick samples at depths exceeding those possible via standard confocal 
microscopes. The TriM-scope achieves this by enabling customization of multiple imaging 
configurations tailored to the sample and experiment goals. This flexibility enables the scanner unit to 
couple into either an upright or inverted microscope body, accept the free space coupling of multiple 
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excitation sources and multi-point beam scanning and detector types and locations optimized to the 
specimen being imaged.  
Figure 6. Intravital in vivo imaging and Fluorescence recovery after photobleaching 
(FRAP) to monitor E-cadherin dynamics. (A) Example of an optical window chamber 
containing a tumor implanted on the back of a CD-1 nude mouse. Inset: confocal image of 
GFP-E-cadherin expressing tumor cells acquired using optical window chambers, a major 
blood vessel is outlined. Scale bar 50 μm. (B) A representative FRAP recovery curve after 
photobleaching of a region of GFP-E-cadherin at the plasma membrane in vivo. 
 
The TriM-scope has two light input ports and the type of sources used are typically in the pulsed 
titanium sapphire (Ti:Sapphire) or optical parametric oscillators (OPO) class of laser. OPO cavities are 
pumped by the IR output from a Ti:Sapphire laser and which, through the choice of optical crystal, can 
produce excitation source light up to 1,400 nm. The generation of far-red shifted excitation has the 
obvious advantage of reduced scattering and absorption while passing through dense tissue, but also 
enables excitation of fluorescent probes in the NIR resulting in fluorescence that also suffers less 
scattering and absorption than the typically used GFPs. In addition to optimizing the delivery of 
excitation light, the TriM-scope design optimizes the detection of generated light through the 
placement of sensitive photo-multiplier tube (PMT) detectors as close to the sample as possible. By 
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placing the PMT detectors directly behind the objective in both epi- or trans-illumination geometry the 
optical emission path length is significantly reduced when compared with standard confocal 
microscopes, thereby, maximizing sensitivity. However, if the experimental priority is the rate of 
acquisition, for example kinetic monitoring of drug responses, instead of depth penetration or 
sensitivity, then the option of multiplexing the excitation beam into a maximum of 64 separate beams 
allows the generation of multiple emission spots which can be imaged simultaneously using a CCD 
camera. Beam-splitting reduces the time to image a region of interest compared to imaging with a 
single beam, however, this approach is associated with a reduction in the power per excitation spot as 
it is distributed between the generated spot pattern, meaning that scattering will have a more apparent 
effect. 
Research in several disease areas have benefited significantly from intravital confocal microscopy 
of preclinical models, most notably tumor biology. Pioneering intravital microscopy studies on tumor 
invasion in vivo have provided novel mechanistic insights with new pro-invasive roles being assigned 
to inflammatory macrophages and collagen fibres [68-70]. Recent studies exploiting the unique 
photoactivation and photobleaching properties of fluorescent probes have provided further mechanistic 
insight into specific biological mechanisms of disease and therapeutic response [26,27]. The 
application of optical windows in conjunction with localized photobleaching of GFP-labeled  
E-cadherin expressed at adherens junctions in engineered tumor cells has been used to monitor  
E-cadherin dynamics both in vitro and in vivo [27] (Figure 6). E-cadherin represents a family of 
transmembrane cell adhesion molecules that bind to the E-cadherin molecules on adjacent cells to 
mediate cell-cell adhesion. Thus, dynamics play a critical role in regulating inter-cellular adhesion 
between epithelial cells and many epithelial derived tumors. Experimental validation demonstrates that 
quantification of E-cadherin mobility into photobleached areas provides a preclinical measure of E-
cadherin function and cell adhesion strength. E-cadherin mobility recorded, following exponential 
curve fitting, as the half-time of recovery provides a rapid and robust quantitative measure of E-
cadherin function and inter-cellular adhesion in vivo [27] (Figure 6B). Photoactivation of a caged (non-
fluorescent) plasma membrane targeting probe provides quantitative assessment of protein diffusion at 
the plasma membrane and in parallel with photobleaching can be used to quantify the proportion of the 
immobile fraction of protein stabilized at cell-cell junctions [27]. These approaches have been used to 
confirm the mechanism-of-action of small molecule kinase inhibitors [26,71].  
The instantaneous readouts provided by such intravital imaging methods are in stark contrast to 
long-term metastasis models that can take up to several months to assess tumor invasion. Rapid image 
based evaluation of drug responses directly within the tumors of live animals facilitate more accurate 
scheduling and dosing, require fewer animals and accelerates the evaluation of preclinical response 
enabling the chemical optimization of lead compounds based on quantifiable in vivo biological 
endpoints. Interestingly, the dynamics of E-cadherin-GFP and plasma membrane diffusion rates in 
tumor cells implanted in vivo differ significantly between identical cell clones cultured on in vitro 2D 
culture substrates [27]. In addition, the observed effect of a licensed kinase inhibitor drug, dasatinib 
upon increasing the immobile fraction of E-cadherin in vivo was not observed when the cells where 
cultured on standard 2D plastic substrates. Critically, these studies demonstrate that 2D in vitro culture 
conditions do not accurately recapitulate the in vivo pharmacological mechanism-of-action of dasatinib 
and possibly other drugs , suggesting that 2D in vitro cell based models commonly used in high-
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content biology poorly predict in vivo drug response. The application of precise image-based 
monitoring of protein dynamics and physiological responses in vivo and in vitro may help calibrate the 
predictivity of in vitro model systems and ensure development of more predictive in vitro high content 
assays.   
Figure 7. Intravital in vivo photoswitching to monitor tumor invasion. (A) Images from a 
time series acquired from a GFP expressing squamous cell carcinoma (SCC) xenograft 
expressing wild-type FAK (green: GFP, purple: confocal reflectance of extracellular 
tissue), scale bar 50 μm. Lower panel represents co-localized images from the time-series 
showing tracked single cell movement within tumors (green, 0 seconds; red, 100 seconds; 
blue, 300 seconds). White arrows indicate direction of cell movement. (B) Images 
represent Dendra2 labeled SCC FAK-wild-type expressing cells imaged using optical 
window chambers at 0, 6, and 24 hours post photo-switching (green, unswitched; red, 
switched). Scale bar 100 μm. Graph represents quantification of the total area covered by 
red fluorescence at sequential time-point following photo-switching. 
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Non-invasive, repeated imaging of single cells expressing photoswitchable probes in real-time has 
recently been used to examine breast cancer motility and intravasation [23]. This approach has 
facilitated in the assessment of therapeutic intervention on other tumor types, including the brain, and 
has also been utilized to monitor the cross-linking and quantity of surrounding ECM components at 
different stages of drug treatment within the same animal [24,25,72]. Cell tracking algorithms have 
commonly been used to provide quantitative analysis of cell migration in vivo by following fluorescent 
labeled cells (Figure 7A), however the statistical robustness of such methods are limited by the low 
number of events recorded. Simultaneous photoactivation of a population of Dendra2 expressing cells 
followed by temporal analysis of distribution patterns of labeled tumor cell populations provides a 
more robust quantitative assessment of in vivo tumor migration [71] (Figure 7B). 
The application of specific fluorescent reporters of protein activity in conjunction with intravital 
microscopy enables specific pathway analysis in vivo with high spatial and temporal dynamics. Recent 
studies using a Smad2-GFP fusion reporter that translocates to the nucleus upon TGFb signaling was 
used to monitor TGFb mediated signaling in migrating Mtln3E tumor cells transplanted in vivo [73]. 
Time-lapse analysis reveals TGFb signaling activity and smad2-GFP nuclear localization in single 
moving cells, whereas, smad2 reporter remained cytoplasmic in cells invading in a collective manner 
or in non-motile cells [73]. This data implies that reversible TGFb signaling can regulate the 
mechanism of breast cancer cell invasion in vivo and further suggests transient TGFb signaling is an 
important determinant of tumor metastasis. Such transient events would be difficult to ascertain from 
fixed endpoint studies which can often lead to conflicting hypotheses in the absence of temporal 
information. 
A recent study using multi-photon based FLIM-FRET demonstrated for the first time the capacity 
to apply FLIM to detect sub-cellular activation of protein species upon therapeutic intervention in live 
animals [74]. These studies demonstrated the presence of a distinct fraction of RhoA protein activity at 
the poles of invasive pancreactic ductal adenocarcinoma (PDAC) cells expressing mutant p53R172H 
protein [74]. Figure 8A displays images from organotypic cultures showing distinct regions of RhoA 
activity at the front of invading cells (Figure 8A middle and right panels). The preliminary finding that 
RhoA was spatially regulated during invasion was achieved using complimentary organotypic 3D 
matrices involving co-culture of pancreatic tumor cells on top of a fibrillar collagen Ι gel and 
embedded human fibroblasts (Figure 8A, left hand panel, H&E). This allowed the 3D manipulation 
and fluorescent lifetime imaging of RhoA activity during invasion to be investigated in a complex in 
vitro setting prior to in vivo examination of this biological process (see Figure 8A, middle and right 
hand panel). Importantly, this pool of RhoA activity at the front and rear of cells correlates with 
invasive potential in vivo and is absent in p53fl null PDAC cells in vivo (Figure 8B, [74]). Such 
detailed spatial analysis of protein activity within individual cells provided by in vivo FLIM enables 
the quantification of dynamic molecular events operating under precise subcellular control at a single 
cell level and thus intractable to standard biochemical techniques. The application of such technologies 
as drug response biomarkers or surrogate markers of drug activity provide precise quantification of 
biochemical signals and pharmacological response in vivo. The applications of these technologies 
display early promise as a new type of kinetic pharmacodynamic biomarker for preclinical drug 
evaluation studies. Analysis of kinetic biomarkers using a variety of distinct technologies including 
live cell imaging offers several advantages over static markers such as more sensitive quantification of 
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flux through biochemical pathways and dynamic phenotypic response in integrated living systems 
[75]. Application of such methods to high quality preclinical models of disease, including genetically 
engineered humanized mouse models that utilize Cre-lox recombination technology to recapitulate the 
genetics and pathophysiology of human disease and incorporate fluorescent reporters, further enhance 
preclinical evaluation under appropriate biological context [76-79].  
Figure 8. Protein activity monitored by multiphoton-based FLIM-FRET in 3D organotypic 
assays and in vivo live mouse model. (A) Left panel: H&E-stained sections of mutant 
p53R172H -driven PDAC cell invasion within collagen Ι/fibroblast organotypic matrix 
culture. Middle panel: Representative fluorescence images of mutant p53R172H cells 
expressing the Raichu-RhoA reporter (green) within the matrix during invasion (~150 µm). 
Right panel: Corresponding life-time map of RhoA activity in mutant p53R172H cells in the 
presence of a chemotactic gradient. Red arrows indicate representative cells examined at 
depth by multi-photon based FLIM-FRET. Low basal RhoA activity is represented in the 
life-time color maps with red/yellow colors, while high RhoA activity is represented as 
blue on the color map. (B) Protein activity monitored by multiphoton-based FLIM-FRET 
in vivo. Left panel: p53fl PDAC cells expressing the RhoA-Raichu reporter (green) within a 
tumor. Blood vasculature is highlighted by tail vein injection of Qtracker 655 quantum dots 
(red). Right panel: Corresponding life-time map of RhoA activity in vivo.  
 
6. Biosensors 
The discovery and application of natural fluorescent proteins, such as green fluorescent protein 
(GFP), as functional biosensors of protein activity and cellular contrast agents has revolutionized the 
study of protein function, location and cell activity in intact cells and living organisms [80,81]. The 
development of engineered cell lines stably incorporating fluorescent protein reporter molecules has 
Pharmaceutics 2011, 3                   
 
 
161
contributed to the increased throughput and application of both fixed endpoint and live cell high 
content analysis screens in drug discovery [82-84].  
Figure 9. In vivo imaging with Quantum dots. (A) 3D rendered image of blood vasculature 
in vivo labeled by tail vein injection of mouse model with Qtracker 655 quantum dots;  
(B) Contextual imaging of cells in vivo. p53fl pancreatic ductal adenocarcinoma cells 
expressing plasma membrane bound GFP (green) within an in vivo tumor in live mouse. 
Blood vasculature is highlighted in red by tail vein injection of Qtracker 655 quantum dots.  
 
Recent developments in the optimization of optical probe design specifically tailored towards live 
cell imaging applications are advancing both the variety of applications and quality of experimental 
investigation. Such advances include genetic mutagenesis of fluorescent proteins to give rise to distinct 
spectral properties facilitating multiplexing or specialized spectroscopic techniques such as 
photoactivation or photoswitching [21,28,85]. The discovery and development of more stable 
monomeric red and far-red fluorescent proteins minimizes perturbation of protein structure and 
function in living systems while increasing the penetration of fluorescent signals through deep tissue 
[85-87]. Chemical optimization of fluorescent dyes based on organic small molecules has produced 
fluorescent probe conjugates with more efficient spectral properties for live cell imaging applications 
[88-90]. Further chemical design of peptide scaffolds that act as substrates for specific enzymes and 
which incorporate fluorescent reporters of enzyme activity have further expanded the application of 
image-based biosensors in live cell and live in vivo models [91-93]. Advances in nanotechnology have 
created light emitting nanoparticles, such as quantum dots that possess superior spectral properties and 
greater flexibility as functional reporters [94]. Quantum dots are small nanocrystals which exhibit high 
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extinction coefficients and quantum yields that make them brighter and more photostable than 
fluorescent proteins or typical fluorescent dyes. The broad excitation and tunable emission properties 
of quantum dots enables the design of nanoparticles with broad excitation but narrow emission 
properties within the near infrared fluorescent (NIRF) window of optimal tissue penetration. High 
photostability, superior brightness, flexible NIRF emission wavelengths and thus increased sensitivity 
exhibited by quantum dots are ideal properties for deep tissue imaging in vivo and long term sequential 
imaging in live specimens [95]. Figure 9B demonstrates GFP labeled pancreatic ductal 
adenocarcinoma (PDAC) cells in vivo (green) with bloodvessels labeled by intravenous injection of 
quantum dots in red, thus, providing contextual information and orientation to the in vivo location of 
tumor cells (Figure 9). 
Table 1. Selected list of commercially available live cell imaging probes, applications and vendors. 
Probe Application Vendor 
PremoTM FUCCI Cell cycle sensor Cell-cycle Invitrogen 
PremoTMAutophagy Sensor (LC3B-RFP or GFP) Autophagy Invitrogen 
PremoTMCalcium Sensor Ca2+ signaling Invitrogen 
CellLightTMHiston2BGFP Nuclear morphology Invitrogen 
CellLightTMActin/Tubulin GFP/RFP Cytoskeletal dynamics Invitrogen 
CellLightTMTalin GFP/RFP Adhesion dynamics Invitrogen 
Human EGFR live cell fluorescent biosensor assay EGFR signaling dynamics Sigma 
CompoZr cellular reporter cell lines beta-actin, 
tubulin alpha-1B chain, LamininB1, HMGA1 
Cytoskeletal dynamics Sigma 
Lysotracker & LysoSensor Lysosomes Invitrogen 
TMRE Mitochondria function Invitrogen 
pHrodoTMIndicators Phagocytosis & Endocytosis Invitrogen 
NucView Apoptosis (caspase activity) Biotium 
MitoView633 Mitochondrial function Biotium 
Sulforhodamine 101-annexin V apoptosis or 
TexasRedTM-annexinV 
Apoptosis Biotium 
CellBrite Cytoplasmic membrane labeling kits 
(Neuro-DiO) 
Cell Tracking Biotium 
DiO/DPA FRET pair Membrane potential Biotium 
Cell TraceTM Violet Cell proliferation Invitrogen 
MMPSense  MMP activity PerkinElmer 
ProSense  Cathespin B, L, S, plasmin activity PerkinElmer 
OsteoSense  Bone turnover PerkinElmer 
AnnexinVivo Apoptosis PerkinElmer 
Angiosense & Angiospark(pegylated-nanoparticles) Vascular Labeling PerkinElmer 
IntegriSense  Angiogenesis/tumor cell metastasis Perkin Elmer 
ReninSense  Renin activity Perkin Elmer 
Neutrophil Elastase  Neutrophil Elastase activity Perkin Elmer 
CatK  Cathepsin K proteinase activity Perkin Elmer 
CatB  Cathepsin B protease activity Perkin Elmer 
Qtracker quantum dots Cell/vascular labeling Invitrogen 
FM 4-64                                                       Membrane label                           Invitrogen 
Acrivlavin        cell label/mask                              Sigma 
Carbocyanine dye DiΙ, DiO                  Membrane label                           Invitrogen 
Fluorescent lectins                                       Bloodvessel endothelium     Invitrogen 
Fluorescent dextran                                     Vascular labeling                            Invitrogen 
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The advances in fluorescent probe design described above provide a number of advantages for long 
term study in live-cell in vitro, ex vivo or in vivo models, such as, enhanced tissue penetration, reduced 
spectral overlap with tissue autofluorescence, reduced risks of phototoxicity, photobleaching and 
perturbation upon protein function. The commercial availability of expanding portfolios of optical 
imaging probes (Table 1) has contributed to a dramatic increase in the number of live cell imaging 
investigations that can be routinely performed. Such advances in probe design have been 
complemented by advances in multiphoton confocal microscopy and automated kinetic imaging 
technology for visualizing fluorescent reporters in live systems. Thus, the mutual benefits of 
fluorescent probe design and platform technologies for detecting fluorescent reporters are synergistic 
and have been instrumental in driving the most significant advances in the field of optical imaging 
over the past decade. 
7. Conclusions  
The latest advances in live cell imaging technologies and functional fluorescent reporters have 
stimulated the development of a number of innovative live-cell imaging techniques providing detailed 
temporal profiling of cell behavior and dynamic molecular events in complex in vitro and in vivo 
model systems. High resolution in vitro and intravital in vivo live imaging applications are heralding a 
new era of “high-definition” drug response profiling. Profiling drug candidates across dynamic in vitro 
and in vivo live imaging assays can provide unique insights into therapeutic mode-of-action and robust 
quantification of transient responses. Fluorescent based biosensors of cell phenotype and target activity 
in vivo can act as early surrogate proof-of-mechanism or proof-of-principal kinetic biomarkers, thus 
facilitating precise pharmacodynamic and efficacy studies directly within diseased tissue in live 
animals. The precise temporal and spatial information on cellular and tissue phenotypes provided by 
live imaging approaches provides additional biological context and refined temporal information for 
identifying genomic or proteomic profiles of pathophysiology and or drug response. Live cell imaging 
applications in drug discovery are largely target-agnostic and encompass large areas of biological 
space and thus ideal for opportunistic drug reprofiling or drug combination studies. Live cell imaging 
is also an ideal companion technology for leveraging additional value from genome-wide siRNA 
screens and emerging stem cell differentiation studies. A key future prospect of live imaging in drug 
discovery applications is uncovering precise and novel phenotypic information from complex in vitro, 
ex-vivo and in vivo systems. Thus, live-cell imaging may provide new insight into old drugs and old 
model systems. A critical issue for current drug discovery strategies is determining whether image-
based endpoints provide greater predictive power of clinical response outcomes over standard 
preclinical measurements. Retrospective studies performed on approved drugs and clinical trial 
failures may help identify which image-based endpoints, biomarkers and experimental models are 
predictive of clinical outcome. It is likely that a multiparametric approach encompassing several 
image-based endpoints and a suite of models systems will deliver the optimal predictions of drug 
efficacy or at least facilitate clinical positioning, dosing strategies and thus more effective clinical trial 
designs. 
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